


Bacterium may decrease effectiveness of immunotherapy

January 25 2023, by Béatrice St-Cyr-Leroux



Association between the *H. pylori* seropositivity status and clinical outcomes in 97 patients with advanced melanoma. A. Stacked barplot between *H. pylori* seropositivity status in terms of ORR in 97 patients with advanced melanoma. CR; complete response. PR; partial response, SD; stable disease, PD; progressive disease analyzed using Chi-square test. B. Kaplan–Meier curve of overall survival in 97 patients with advanced melanoma. C. Kaplan–Meier curve of progression-free survival in 97 patients with advanced melanoma. D. Stacked barplot between *H. pylori* seropositivity status in terms of autoimmune toxicities

in 97 patients with advanced melanoma. Credit: *OncoImmunology* (2022). DOI: 10.1080/2162402X.2022.2096535

Helicobacter pylori is a bacterium that colonizes the stomach lining and is found in more than half of the global population, making it one of the most widespread bacterial infections in the world.

Most people with an *H. pylori* infection have no symptoms, but it can result in gastric ulcers and even stomach cancer.

A new Canadian study has found that seropositivity for the bacteria—meaning a blood test has confirmed the presence of antibodies against a previous *H. pylori* infection—may decrease the response to immunotherapy in people with metastatic [melanoma](#), an advanced skin cancer.

The work is published in the journal *OncoImmunology*.

Dr. Marion Tonneau led the study as part of a CHUM Research Centre team under Université de Montréal medical professor Dr. Bertrand Routy, who looks at how combining immunotherapy with [fecal transplantation](#) to modify [gut microbiomes](#) can help melanoma patients.

Routy and his team studied nearly 100 patients with advanced melanoma who were treated with immunotherapy, focusing on the effect of the billions of gut-dwelling bacteria on the immune system. They found that patients who tested positive for *H. pylori* tended to respond more poorly to immunotherapy than patients who were negative, and had significantly shorter overall survival rates.

The study subjects all received immune checkpoint inhibitors (ICI), a

form of [immunotherapy](#) that is currently at the forefront of treatment therapies for melanoma patients. ICI specifically stimulate the immune system to target cancer cells.

Routy's recent work has led researchers to take the microbiome into account in cancer research and treatments. Several studies to improve the efficacy of ICI by modifying intestinal microbiota—such as through fecal transplantation—are in the works.

Current research has been more broadly focused on intestinal microbiota, on the lower gastrointestinal tract, including the intestines, appendix and rectum. But Tonneau believes the new findings should encourage immuno-oncologists to take a keener interest in the upper gastrointestinal tract (the mouth, pharynx, esophagus, and stomach), as well.

"After all, *H. pylori* is found in the lining of the stomach, and it is present in over 50 percent of the world's population," she said. "Our study suggests that *H. pylori*, in addition to affecting the stomach, can potentially affect systemic immune response, notably by modifying the polarization of T lymphocytes. This is further evidence that microbiota play a role in the development of cancers, and not just intestinal cancers."

The next steps, according to Tonneau, are to corroborate these findings in broader prospective studies and to develop new strategies to eradicate *H. pylori* in patients undergoing immuno-oncological treatments.

More information: Marion Tonneau et al, *Helicobacter pylori* serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors, *OncoImmunology* (2022). [DOI: 10.1080/2162402X.2022.2096535](https://doi.org/10.1080/2162402X.2022.2096535)

Provided by University of Montreal

Citation: Bacterium may decrease effectiveness of immunotherapy (2023, January 25) retrieved 2 May 2024 from

<https://medicalxpress.com/news/2023-01-bacterium-decrease-effectiveness-immunotherapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.